Schering Sees No Impact From Imports; Not Attractive To “Parallel Traders”
Schering-Plough sees one advantage to operating as a smaller pharmaceutical player: little or no impact from a potential U.S.-sanctioned drug importation policy
You may also be interested in...
The Senate Republican leadership's reimportation bill will focus on wholesale imports from Canada and leave any decision about future expansions in parallel trade up to FDA
AARP is endorsing prescription drug reimportation from Canada as a measure to help control the cost of drugs
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011